Pantoprazole Towa (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Towa is a proton pump inhibitor that acts on the gastric acid secretion pathway, providing relief in several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): helps heal erosive esophagitis and reduces heartburn episodes.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduction of gastric acidity.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild, transient headache reported in clinical studies.
• Diarrhea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased gas formation.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Acute interstitial nephritis: kidney inflammation with reduced urine output.
• Severe hypersensitivity: rash, angioedema, or anaphylaxis.
• Osteoporosis‑related fractures: increased risk with long‑term use.
• Vitamin B12 deficiency: reduced absorption leading to anemia.
• Liver enzyme elevation: abnormal hepatic function tests.

Before initiating therapy with Pantoprazole Towa, consider the following safety measures:

• Assess renal function: adjust use in severe renal impairment.
• Review hepatic status: use with caution in moderate to severe liver disease.
• Evaluate need for long‑term therapy: weigh benefits against potential bone fracture risk.
• Monitor for infections: be alert to signs of C. difficile or pneumonia.
• Pregnancy and lactation: prescribe only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation.
• Methotrexate: reduced renal clearance; check serum levels.
• Digoxin: slight increase in serum concentration; observe for toxicity.